Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Lilly will acquire Centessa for $38.00 in cash per share plus one CVR worth up to $9.00 (total up to $47.00/share), implying ~ $6.3bn upfront equity value and up to ~$7.8bn including CVRs. The deal represents a ~40.5% premium to Centessa's 30-day VWAP and targets Centessa's OX2R agonist portfolio led by cleminorexton (Phase 2a); CVR payouts (up to $9) are contingent on three FDA-approval milestones. Transaction to be effected by a scheme of arrangement and expected to close in Q3, subject to Centessa shareholder approval, High Court sanction in England & Wales and customary regulatory conditions.

Analysis

Lilly’s purchase materially accelerates its entry into a mechanistically differentiated corner of sleep medicine; the real strategic edge is owning an orexin agonist platform that can both displace stimulant-centered prescribing and create new combination/regimen opportunities in neurodegeneration and post-stroke fatigue. Expect prescribing mix shifts over 12–36 months: if Phase 3 confirms symptomatic and cognitive signal durability, office visits and diagnosis rates for hypersomnolence disorders will rise, enlarging addressable market and increasing lifetime patient value per prescriber.

Second-order industrial winners are specialty CMOs, clinical pharmacology sites and central nervous system CROs that can run large, placebo-sensitive wakefulness trials; they will capture outsized billings during the next 6–24 months as programs move into registration. Conversely, manufacturers and distributors of generic stimulants and off-label amphetamine prescriptions face gradual market share erosion, particularly in sleep-disorder clinics that adopt orexin agonists for their more targeted mechanism and favorable adverse-event profiles.

Key reversal risks are regulatory/endpoint uncertainty and commercial adoption inertia: CNS endpoints for excessive daytime sleepiness are noisy, and payors may demand comparative-effectiveness data versus low-cost generics, stretching commercial ROI timelines into years. Merger-related execution risks (integration, retention of the acquirer’s neuroscience team) and the sensitivity of valuation to long-term penetration assumptions make near-term equity moves more merger-arb than pure growth exposure.

Key Decisions for Investors

• Merger-arb: buy CNTA ADS if the market price offers ≥1.5% discount to the implied cash+CVR consideration (monitor CVR pricing separately). Timeframe: hold until deal closing window (next 3–6 months). Risk/Reward: limited upside to spread capture if deal closes; downside is full deal break risk — size position at 1–2% of portfolio and hedge with index puts.
• Long LLY equity or a 9–15 month call spread (buy calls, sell higher strike) to capture integration upside and pipeline optionality. Timeframe: 6–18 months. Risk/Reward: asymmetric — modest funding cost for exposure to multiple CNS indications; primary risk is share congestion if acquisition accounting dilutes near-term EPS.
• Tactical supply-chain play: initiate a small-to-medium long in a broadly diversified CMO/CRO basket (e.g., CTLT, TMO) to capture trial and scale-up work over 6–24 months rather than single-name risk. Timeframe: 6–24 months. Risk/Reward: steady revenue tail from neuro trials; downside is macro capex slowdown or contract re-shoring policies.
• Hedge/Pair: pair LLY long with a short position in a mid-cap stimulant/generic specialist (size small) to neutralize market beta while isolating orexin commercial risk. Timeframe: 6–24 months. Risk/Reward: reduces macro exposure; risk is if stimulants retain market share faster than expected due to pricing or access barriers for new entrants.